Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

What happened

Teva and Samsung Bioepis announced a license and commercialization agreement for two FDA-approved immunology biosimilars. Teva gets U.S. commercialization rights to etanercept-ykro at closing, while rights to infliximab-abda transfer in Q3 2027. Samsung Bioepis keeps regulatory oversight and manufacturing. The deal is expected to close by the end of 2026.

Confirmed

Global impact / market context

The deal adds two biologic treatment options to Teva's U.S. immunology portfolio. Teva calls biosimilars an important part of its Pivot to Growth strategy, which aims to build a stronger portfolio and expand access to medicines. Teva's future U.S. launch timing for etanercept-ykro will be announced later.

Confirmed

Biosimilars are near-copies of existing biologic drugs, usually sold at lower prices. Adding them can lift a seller's product range and revenue, but price competition can reduce profit per sale. The staggered transfer of rights, with infliximab-abda arriving in 2027, spreads Teva's commercial build-out over time.

Analyst inference

What to watch

1. The transaction depends on customary closing conditions, including necessary regulatory approvals, and is currently anticipated to close by the end of 2026, which means the rights transfer could slip if approvals take longer. Confirmed
2. Teva has proposed to commercialize etanercept-ykro in the U.S. but has not set a launch date, so watch for a future announcement on when sales will begin. Proposed
3. Watch whether U.S. payers and doctors accept these biosimilars and at what prices, since lower pricing would affect Teva's revenue and profit per sale on both products. Analyst inference

Evidence

• globenewswire.com